Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck Gets European OK for Keytruda in Triple-Negative Breast Cancer

10/22/2021 | 05:21am EST

By Colin Kellaher

Merck & Co. on Friday said the European Commission approved expanded use of its blockbuster cancer drug Keytruda in combination with chemotherapy for the first-line treatment of certain patients with locally recurrent unresectable or metastatic triple-negative breast cancer.

The Kenilworth, N.J., drugmaker said the approval, its first for Keytruda in Europe in a breast-cancer setting, covers the treatment of adults whose tumors express PD-L1 with a combined positive score of at least 10 and who haven't received prior chemotherapy for metastatic disease.

Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is approved in numerous indications across a range of cancers around the world.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

10-22-21 0721ET

All news about MERCK & CO., INC.
08:31aMerck Announces Five-Part US Dollar Issuance With Maturities From 5-40 Years
MT
06:49aGuggenheim Downgrades Merck to Neutral From Buy
MT
06:42aMerck Pledges Additional $150 Million to End Maternal Mortality Inequities
MT
06:16aMerck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality..
BU
05:46aNGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 ..
AQ
05:46aMerck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational,..
AQ
12/06Merck Pausing Enrollment for Two Trials of Oral Islatravir
DJ
12/06Merck Pauses Two Phase 3 Trials Evaluating Islatravir for Pre-Exposure Prophylaxis
MT
12/06Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational,..
BU
12/06Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational
CI
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 572 M - -
Net income 2021 12 378 M - -
Net Debt 2021 20 562 M - -
P/E ratio 2021 15,1x
Yield 2021 3,54%
Capitalization 185 B 185 B -
EV / Sales 2021 4,24x
EV / Sales 2022 3,55x
Nbr of Employees 73 500
Free-Float 70,5%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 73,42 $
Average target price 95,25 $
Spread / Average Target 29,7%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-11.66%185 455
JOHNSON & JOHNSON3.53%428 955
ROCHE HOLDING AG17.23%322 390
PFIZER, INC.44.09%288 950
NOVO NORDISK A/S65.08%245 091
ELI LILLY AND COMPANY45.45%223 321